Lenz Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in LENZ Therapeutics, Inc.
NASDAQ
Multiple Squarepoint entities have collectively reported beneficial ownership of over 5% of LENZ Therapeutics, Inc. common stock.
NASDAQ
FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 11.8% of LENZ THERAPEUTICS INC common stock as of December 31, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 4.9% Stake in LENZ THERAPEUTICS
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.9% of LENZ THERAPEUTICS, INC.'s common stock as of December 31, 2025.
NASDAQ
Paradigm BioCapital Advisors LP and its affiliates have reduced their beneficial ownership in LENZ Therapeutics, Inc. to below the 5% threshold, as disclosed in an amended Schedule 13G filing.
NASDAQ
Steven A. Cohen's Point72-affiliated entities have disclosed a 4.8% beneficial ownership stake in LENZ Therapeutics, Inc. as of September 30, 2025.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 15.0% in LENZ THERAPEUTICS INC's common stock as of October 31, 2025.
NASDAQ
BlackRock, Inc. has reported a 5.1% beneficial ownership stake in LENZ THERAPEUTICS, INC. as of September 30, 2025, through a Schedule 13G filing.
NASDAQ
Paradigm BioCapital Advisors LP, along with affiliated entities and Senai Asefaw, M.D., has disclosed a passive beneficial ownership of 5.2% of LENZ Therapeutics, Inc.'s common stock as of March 20, 2025.